Month: February 2026

The Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Reducing Pathologic Scar Formation After Median Sternotomy

Summary: This cross-sectional observational study (n=100 patients ≥6 months post-median sternotomy on continuous antihypertensives) investigated whether ACE inhibitors (ACEIs, n=33) or angiotensin II receptor blockers (ARBs, n=35) influence pathologic scar formation compared to other antihypertensives (n=32). Scar quality was assessed using POSAS v2.0 (Patient and Observer Scar Assessment Scale). Results showed significantly lower keloid formation in ACEI (24.2%) and ARB (25.7%) groups vs. controls (53.1%, p=0.021). Both patient (PSAS) and observer (OSAS) total scores were significantly better in ACEI/ARB groups (p=0.042 and p=0.036). Key subparameters improved: vascularization, pigmentation, thickness, surface appearance (OSAS); pain, stiffness, thickness, irregularity (PSAS). Suggests RAS inhibition (via ACEIs/ARBs) may modulate tissue remodeling and reduce hypertrophic/keloid scarring in hypertensive patients post-sternotomy. Exploratory due to cross-sectional design and variable postoperative times; calls for prospective RCTs to confirm causality and explore mechanisms.

Key Highlights:

• Keloid rate: ~50% lower in ACEI/ARB groups (p=0.021)
• POSAS improvement: Multiple subscores (vascularity, pigmentation, thickness, pain, stiffness) significantly better
• Implication: Common antihypertensives may offer dual benefit for scar quality in cardiac surgery patients
• Limitations: Observational; needs RCTs for causality and dosing

Read full article (subscription may be required)

Keywords: ACEI scarring, ARB keloid, POSAS scale, pathologic scar, median sternotomy

Pressure Ulcers and Mobile Wound Care – A Winning Combination

Summary: This article (lecture-style by Zwelithini Tunyiswa, CEO of Open Wound Research) highlights mobile wound care as a pragmatic solution to pressure ulcer challenges, especially in elderly populations with high prevalence and complexity. Delivers specialized interventions directly at point of care (e.g., facilities/homes) for timely management. Emphasizes integration into practice for better patient outcomes, reduced complications, and sustainable economic growth—no specific data/stats, but stresses clinical advantages over traditional settings.

Key Highlights:

• Challenges: Prevalence/complexity of pressure ulcers in elderly
• Solution: Mobile care for timely/specialized point-of-care treatment
• Benefits: Improved outcomes; economic sustainability/practice growth
• Relevance: Supports accessible advanced care in podiatry/chronic settings

Read article

Keywords: pressure ulcers, mobile wound care, elderly wound management, podiatry chronic care

Expanding the Toolbox for Complex Aorta and Limb Salvage

Summary: This February 2026 article explores advanced strategies for managing complex aortoiliac occlusive disease (AIOD) combined with chronic limb-threatening ischemia (CLTI). Emphasizes multidisciplinary collaboration (vascular surgery, interventional radiology, wound care) to expand treatment options beyond traditional open bypass. Covers endovascular (stenting, atherectomy), hybrid procedures, and open surgery tailored to anatomy, comorbidities, and runoff. Highlights improved patency rates, limb salvage success, and reduced major amputation in high-risk patients through innovative tools and techniques. Stresses preoperative planning, perfusion assessment, and postoperative wound management to optimize outcomes in complex cases.

Key Highlights:

• Multidisciplinary approach key for CLTI + AIOD
• Endovascular/hybrid options expand toolbox
• Improved limb salvage and patency
• Relevance: Critical for ischemic DFUs and lower extremity wounds

Read full article

Keywords: limb salvage, CLTI, aortoiliac disease, multidisciplinary vascular

Knowledge and Practices in Diabetic Foot Ulcer Prevention Among Patients with Diabetes Mellitus in Gauteng, South Africa

Summary: This research assesses awareness and behaviors related to diabetic foot ulcer prevention among diabetes patients in Gauteng. Findings reveal moderate knowledge but inconsistent daily practices (foot checks, footwear, hygiene), underscoring the need for structured patient education and community programs to reduce DFU incidence and amputations.

Key Highlights:

• Knowledge gaps in daily self-care routines
• Low adherence to preventive behaviors
• Call for culturally tailored education

Read full study

Keywords: DFU prevention, patient education, South Africa diabetes

Podiatric Care Associated with Reduced Mortality and Enhanced Amputation-Free Survival

Summary: This retrospective analysis demonstrates that podiatric care in the management of diabetic foot ulcers (DFUs) is linked to reduced all-cause mortality and longer amputation-free survival. Patients receiving podiatry services showed better outcomes compared to those without, highlighting the value of early, specialized foot care in multidisciplinary teams.

Key Highlights:

• Lower mortality risk with podiatric intervention
• Extended amputation-free survival
• Supports routine podiatry referral in DFU protocols

Read full study

Keywords: podiatric care, DFU mortality, amputation-free survival

OIG Watching Wound Care: Your Debridement Codes Are in the Crosshairs

Summary: February 2026 Pulse post warns of OIG scrutiny on wound care debridement codes (11042-11047). Focus: Upcoding (deeper than documented), insufficient notes (missing depth, tissue types, debrided amount), lack of medical necessity (no conservative care failure proof). Risks: Audits, repayments, penalties. Advice: Detailed documentation (pre/post photos, measurements, tissue description, rationale), compliance training, internal audits, use of modifiers. Ties to high reimbursement value and fraud concerns; urges proactive measures for sustainability in advanced wound care.

Read article

Keywords: OIG audit, debridement coding, wound care compliance

How to Assess Wound Exudate

Summary: Article provides practical guide to assessing wound exudate in chronic/hard-to-heal wounds. Exudate types: Serous (clear), serosanguineous (pink), sanguineous (bloody), purulent (yellow/green), fibrinous (thick). Volume: Low (moist), moderate (soaked dressing), high (leaking). Assessment: Visual (color, consistency, odor), volume estimation (dressing saturation), peri-wound skin (maceration). Tools: Exudate scales, photography, patient input. Management: Match absorptive dressings (foam, alginate, superabsorbent), topical agents (antimicrobials for infected), frequency changes. Emphasizes exudate as healing indicator (excess delays, optimal moist environment promotes). Relevant for infection/biofilm detection and advanced therapy selection.

Read article

Keywords: wound exudate, exudate assessment, moisture balance

Global Preventive Foot Care

Summary: 2025 document from Wound Canada provides a global view on preventive foot care. Focuses on high-risk groups (diabetes, neuropathy, PAD, elderly); strategies: Annual screening (monofilament, tuning fork, vascular checks), patient education (self-care, footwear), offloading (custom orthotics, shoes), multidisciplinary teams, policy advocacy. Addresses disparities (low-resource settings, cultural barriers), evidence-based tools (IWGDF guidelines), and prevention’s role in reducing DFU/amputation burden. Calls for standardized global approaches, research, and implementation to improve outcomes equitably.

Read document

Keywords: global foot care, DFU prevention, screening strategies

Letter to CMS Requesting That Blood-Derived Products HCPCS Code G0465 Be Considered Under Potentially Misvalued Code Process

Summary: Advocacy letter from wound care stakeholders to CMS requests review of HCPCS code G0465 (blood-derived products for wound care) under the potentially misvalued code process. Argues current valuation outdated, undervalues products (e.g., PRP, autologous blood derivatives), limits access/innovation, and hinders chronic wound management (DFUs, VLUs). Cites evidence: High costs, clinical benefits (healing acceleration), need for accurate reimbursement to support evidence-based use. Seeks revaluation for fair payment, reduced barriers, and improved outcomes in advanced therapies. Part of broader efforts for sustainable coverage.

Read letter

Keywords: HCPCS G0465, blood-derived products, CMS misvalued, wound care advocacy

Toe Pressure Assessment in Lower Limb Wound Care

Summary: 2025 document from Wound Canada provides guidelines for toe pressure assessment in lower limb wound care. Technique: Photoplethysmography (PPG) or strain-gauge; measures systolic pressure in great toe. Interpretation: Normal >60 mmHg; 30–60 mmHg moderate ischemia; <30 mmHg critical (high amputation risk). Role: Complements ABI (less affected by calcification), detects distal disease in diabetes/PAD, stratifies DFU/CLI risk, guides referral (vascular specialist if low). Benefits: Non-invasive, bedside, reliable in calcified vessels. Recommendations: Routine in high-risk patients, serial monitoring, integration into multidisciplinary pathways. Supports timely intervention to preserve limbs.

Read document

Keywords: toe pressure, lower limb wounds, CLI risk, vascular assessment

Plantar-Plantar Punch Skin Grafts for Wound Caused by Crush Injury

Summary: Case report demonstrates plantar-to-plantar punch skin grafts for a plantar crush injury wound. Technique: Harvest small punch grafts from contralateral plantar glabrous skin, place into recipient bed (debrided, prepared). Outcomes: High take rate, durable coverage, restored weight-bearing function, minimal donor site issues (small punches heal quickly). Advantages: Thick, keratinized grafts match plantar tissue, resist shear/pressure, reduce contracture. Relevant for traumatic plantar defects; supports autologous options in high-stress areas where synthetic grafts may fail. Emphasizes precision placement, offloading, and monitoring.

Read case report

Keywords: punch skin grafts, plantar wound, crush injury, glabrous skin

Simplified and Comprehensive Diabetic Foot Ulcer Guidelines

Summary: March 2026 article presents simplified yet comprehensive guidelines for diabetic foot ulcer (DFU) management. Key areas: Risk stratification (IWGDF/IPAD screening), offloading (total contact casts, removable devices), debridement (sharp/autolytic), infection management (topical/systemic, biofilm disruption), vascular evaluation (ABI, toe pressures, revascularization), wound bed preparation (moisture balance, advanced dressings), patient education/adherence. Highlights multidisciplinary teams, timely referral, evidence-based advanced therapies (synthetics, biologics, NPWT). Simplified for primary care use; comprehensive for specialists. Emphasizes prevention, early intervention, and amputation reduction through standardized pathways and patient-centered care.

Read abstract (subscription may be required)

Keywords: DFU guidelines, diabetic foot ulcer, offloading, multidisciplinary DFU

Green Synthesis of ZnO Nanoparticles: A Sustainable Approach for Wound Healing Applications

Summary: 2026 study develops ZnO nanoparticles via green synthesis (using plant extracts as reducing/capping agents) for wound healing. Advantages: Eco-friendly, low toxicity, cost-effective vs. chemical methods. Characterization: Uniform size/shape, stability, ROS scavenging. In vitro: Strong antibacterial (Gram-positive/negative, including resistant strains), antioxidant (DPPH assay), anti-inflammatory (↓ cytokines), promotes fibroblast migration/proliferation/collagen production. In vivo (rat models): Accelerated closure, granulation, re-epithelialization, angiogenesis in chronic/excisional wounds. Mechanisms: ZnO releases ions for antimicrobial action, modulates ROS signaling for repair. Positions green ZnO NPs as sustainable nanomaterial for topical dressings in chronic wounds (DFUs, burns); potential for composite gels/films. Calls for clinical trials.

Key Highlights:

• Synthesis: Plant-mediated, sustainable.
• Properties: Antimicrobial, antioxidant, pro-healing.
• Applications: Chronic wound dressings.
• Relevance: Green nano-approach for future synthetic therapies.

Read full article

Keywords: green ZnO nanoparticles, wound healing, nano antimicrobial, sustainable synthesis

Towards Limb Preservation

Summary: 2025 document from Wound Canada outlines a national vision for limb preservation in diabetes/chronic lower extremity wounds. Key pillars: Early identification (risk screening, AI tools), multidisciplinary care (endocrinology, vascular, podiatry, wound specialists), evidence-based interventions (offloading, revascularization, advanced dressings/grafts, infection control), patient education/adherence. Addresses inequities (rural/Indigenous access, socioeconomic barriers), high amputation burden, and preventable nature. Recommends standardized pathways, telehealth, real-world evidence, policy advocacy for funding/reimbursement. Emphasizes holistic (glycemic control, nutrition, psychological support) and equitable approaches to minimize major amputations and improve QoL.

Read document

Keywords: limb preservation, Wound Canada, DFU prevention, multidisciplinary care

Surprise! Last-Minute 2025 Reimbursement Changes

Summary: March 2026 article outlines unanticipated late-2025 Medicare reimbursement changes affecting wound care providers. Key updates: LCD revisions (e.g., stricter medical necessity for biologics/skin substitutes, vascular assessment timelines), HCPCS code adjustments (G0465 blood-derived products under review), documentation burdens (e.g., photo proof, longitudinal notes), and MAC-specific policies causing denials spikes. Impacts: Increased administrative load, cash flow disruptions, potential service reductions. Strategies: Proactive audits, template updates, payer education, advocacy via societies. Emphasizes preparation for 2026 PFS rules; warns of cascading effects on advanced therapies (synthetics, NPWT, grafts). Ties to broader policy shifts and provider resilience.

Key Highlights:

• Changes: LCD/HCPCS tweaks, documentation rigor.
• Effects: Denials, revenue risks.
• Solutions: Audits, templates, advocacy.
• Relevance: Critical for sustaining synthetic/innovative care amid policy flux.

Read full article (subscription may be required)

Keywords: 2025 reimbursement changes, Medicare LCD, wound care denials, compliance strategies

Negative Pressure Wound Therapy Assisted Granulation and Grafting Over Exposed Bone and Tendon

Summary: Case report demonstrates NPWT’s role in promoting granulation over exposed bone/tendon in complex wounds (e.g., trauma, debridement defects). NPWT (continuous/intermittent) draws fluid, reduces edema, stimulates angiogenesis/fibroblast activity, fills defects with granulation tissue despite avascular structures. Followed by split-thickness skin grafting on NPWT-prepared bed; outcomes: Successful take, closure, no further exposure complications. Emphasizes protocol (foam bridging, protective layers, infection control) and benefits (downstages reconstruction, limb salvage). Relevant for hard-to-heal wounds with exposed structures; supports NPWT as adjunct in advanced care.

Read case report

Keywords: NPWT exposed bone, granulation promotion, skin grafting

Recent Advances in Nanozymes Toward Diabetic Foot Ulcers

Summary: 2026 narrative review covers recent advances in nanozymes for diabetic foot ulcers (DFUs). Nanozymes: Nanomaterials (metal oxides, carbon-based) mimicking enzymes (catalase, superoxide dismutase, peroxidase, glucose oxidase) with high stability, low cost, tunable activity. In DFUs: Counter hyperglycemia-induced oxidative stress (ROS scavenging), reduce infection (antibacterial), modulate inflammation, promote angiogenesis/collagen via ROS regulation. Examples: MnO2, CeO2, Pt-based nanozymes; glucose oxidase-like for hyperglycemic control. Advantages: Overcome natural enzyme limitations (instability, immunogenicity); synergistic with dressings (hydrogels, films). Preclinical evidence: Accelerated closure, better granulation in diabetic models. Challenges: Biocompatibility, long-term safety, clinical translation. Future: Smart/multi-functional nanozymes for personalized DFU therapy.

Key Highlights:

• Activity: ROS scavenging, antimicrobial, anti-inflammatory.
• Benefits: Stability, cost-effectiveness vs. natural enzymes.
• Applications: Topical delivery in DFUs.
• Relevance: Nano-synthetic enzyme mimics for chronic diabetic wounds.

Read full review

Keywords: nanozymes, diabetic foot ulcers, ROS scavenging, nano therapeutics

An Equitable Vision for Wound Assessment

Summary: 2025 document from Wound Canada outlines an equitable vision for wound assessment across Canada. Addresses disparities: Geographic (rural/remote access), demographic (Indigenous, low-income, immigrant), cultural/language barriers, implicit bias in tools/assessments. Recommendations: Inclusive protocols (culturally safe, trauma-informed), standardized yet adaptable tools (e.g., Skin Tone Tool for diverse pigmentation), training/competencies for providers, telehealth integration, community partnerships, policy advocacy for funding/equity. Emphasizes patient-centered, anti-racist approaches; calls for research/data on inequities and collaborative implementation. Implications: Reduces disparities in chronic wound outcomes (DFUs, VLUs, pressure injuries) in underserved groups.

Read document

Keywords: equitable wound assessment, Wound Canada, cultural sensitivity, disparities wound

A New Partnership to Advance Pressure Injury Prevention and Management

Summary: March 2026 announcement details a new partnership (context: likely SAWC/NPIAP or allied organizations) to advance pressure injury prevention/management. Goals: Enhance education, research, guideline dissemination, tool development, and clinical protocols. Activities: Joint initiatives (webinars, consensus docs, data sharing), improved resources for clinicians (risk assessment, offloading, dressings), focus on high-risk populations (elderly, immobile, diabetic). Ties to rising incidence and economic burden; emphasizes evidence-based, multidisciplinary approaches. Implications: Better outcomes, reduced complications/hospital stays, policy influence.

Key Highlights:

• Focus: Prevention tools, management standards.
• Benefits: Collaborative education/research.
• Relevance: Strengthens pressure injury programs in chronic care.

Read announcement (subscription may be required)

Keywords: pressure injury partnership, prevention management, NPIAP

Treatment of Refractory Leg Ulcer in Patient with Lupus Undergoing Combination Therapy

Summary: Case report details management of refractory leg ulcer in a patient with systemic lupus erythematosus (SLE). Ulcer persistent despite standard care due to autoimmune inflammation, vasculitis, and impaired healing. Treatment: Multimodal combination—aggressive debridement (sharp/autolytic), advanced dressings (e.g., collagen/silver for infection/biofilm), topical agents, compression therapy, systemic lupus management (steroids, immunosuppressants, hydroxychloroquine). Outcomes: Progressive granulation, reduced inflammation, complete closure over months. Emphasizes challenges (recurrent flares, poor perfusion), need for rheumatology/wound collaboration, and tailored regimens. Demonstrates success in inflammatory/refractory ulcers with integrated therapy; relevant for autoimmune-associated chronic wounds.

Key Highlights:

• Challenges: Autoimmune vasculitis delays healing.
• Approach: Debridement + advanced dressings + systemic control.
• Outcome: Full healing; multidisciplinary key.
• Relevance: Insights for complex inflammatory chronic ulcers.

Read case report

Keywords: lupus leg ulcer, refractory ulcer, combination therapy, autoimmune wound

Quantifying and Visualizing the Pressure: Pressure Injury Prevention in the Operating Room

Summary: March 2026 article explores pressure injury prevention in the operating room using pressure mapping technology to quantify and visualize interface pressures between patient skin and OR surfaces (mattresses, tables, positioning devices). High pressures (>32 mmHg prolonged) during surgery contribute to intraoperative pressure injuries (prevalence 8.5–34.5%). Study/methods: Real-time mapping identifies hotspots (sacrum, heels, occiput), correlates with duration/positioning. Interventions: Pressure-redistributing overlays, gel pads, heel protectors, frequent micro-adjustments. Outcomes: Reduced peak pressures, better distribution, lower injury risk. Emphasizes multidisciplinary protocols (anesthesia, nursing, surgeons), documentation, and education. Ties to NPIAP guidelines; calls for routine mapping in high-risk cases (long procedures, immobility). Supports proactive, tech-enabled prevention in surgical/chronic care settings.

Key Highlights:

• Tech: Pressure mapping quantifies hotspots in real time.
• Risks: Prolonged high pressures during anesthesia/immobility.
• Solutions: Offloading aids, positioning changes, protocols.
• Relevance: Prevents iatrogenic pressure injuries in vulnerable patients.

Read full article (subscription may be required)

Keywords: pressure mapping, OR pressure injury, intraoperative prevention, NPIAP guidelines

Expectation Versus Reality in Chronic Wound Care

Summary: February 2026 commentary examines the disconnect between expectations and realities in chronic wound management. Ideal: Fast healing, complete closure, minimal scarring, low recurrence with standard care. Reality: Influenced by comorbidities (diabetes, vascular disease, malnutrition), biofilm/infection, patient factors (adherence, mobility), and wound chronicity—leading to prolonged treatment, high recurrence (e.g., 70% in VLUs within 1 year), and amputation risks in DFUs. Discusses clinician/patient frustrations from unmet expectations, over-reliance on “miracle” products, and underestimation of systemic issues. Recommends realistic goal-setting (e.g., percentage area reduction, pain control, infection prevention), multidisciplinary teams (wound specialists, vascular, nutrition, podiatry), evidence-based advanced therapies (synthetics, biologics, NPWT), patient education (lifestyle, adherence), and longitudinal monitoring. Emphasizes QoL improvements over perfect closure; calls for better communication to align expectations and reduce burnout/dissatisfaction.

Key Highlights:

• Gap: Ideal rapid healing vs. real-world slow/recurrent progress.
• Contributors: Comorbidities, biofilm, non-adherence.
• Solutions: Realistic goals, multidisciplinary, education.
• Relevance: Frames expectations for synthetic/innovative therapies in chronic wounds.

Read commentary

Keywords: chronic wound expectations, patient education, multidisciplinary care, recurrence rates

Nanostructured Lipid Carrier Gels for Wound Healing: A Narrative Review

Summary: 2026 narrative review explores nanostructured lipid carriers (NLCs) in gel form for wound healing applications. NLCs: Hybrid lipid nanoparticles (solid/liquid lipids) overcome SLN limitations (higher loading, stability, sustained release). Gels provide occlusive/moist environment, ease of application, prolonged contact. Benefits: Enhanced encapsulation/protection of actives (curcumin, silver, growth factors, antibiotics), improved skin penetration, controlled release, reduced dosing frequency. Evidence: In vitro/in vivo studies show anti-inflammatory/antimicrobial effects, accelerated closure, collagen deposition, angiogenesis in chronic models (diabetic, burn, infected wounds). Advantages over conventional gels: Better bioavailability, targeted delivery, minimized side effects. Challenges: Scalability, regulatory hurdles, long-term safety. Positions NLC gels as promising platform for chronic/hard-to-heal wounds; calls for clinical trials and combination therapies (e.g., with synthetics).

Key Highlights:

• Advantages: High loading, sustained release, penetration.
• Applications: Infection/inflammation control, regeneration.
• Future: Personalized, multi-active formulations.
• Relevance: Nano-delivery enhances synthetic/bioactive wound therapies.

Read full review

Keywords: NLC gels, nanostructured lipid carriers, wound healing delivery, nano therapeutics

A Season of Reflection and Progress in Wound Management

Summary: December 2025 editorial by John C. Lantis, II, MD, FACS uses the holiday season for reflection on wound care advancements amid uncertainties. Notes stability in tissue/biologic products, shift to online-only journal, surge in international submissions offering diverse insights, upcoming consensus documents on debridement across sites and postoperative dehiscence. Anticipates 18 months of studies on tissue products in DFUs/VLUs, long-term pressure injury outcomes, and atypical wounds. Emphasizes recharging, engaging with content for better patient understanding (medical/psychological/social), and advancing knowledge to reduce suffering, heal wounds, and elevate QoL. Welcomes feedback to enhance article value; highlights Wound Care Collaborative Community contributions (image quality, trial designs, PROs).

Key Highlights:

• Progress: Biologics stability, global research, consensus docs.
• Upcoming: Debridement/dehiscence guidelines; healing trajectory studies.
• Message: Reflect on commitment; focus on patient-centered outcomes.
• Relevance: Year-end overview tying to synthetic/innovative therapies and chronic wound challenges.

Read editorial

Keywords: wound management progress, biologic products, debridement consensus, atypical wounds

Psychological Stress Impairs Wound Healing and Collagen Production, New Review Confirms

Summary: February 2026 review synthesizes evidence linking psychological stress to impaired wound healing. Acute/chronic stress elevates cortisol/catecholamines, disrupting inflammation (prolonged pro-inflammatory phase), reducing fibroblast activity/collagen deposition (↓ type I/III collagen, cross-linking), impairing angiogenesis (↓ VEGF), and delaying re-epithelialization/contraction. Mechanisms: HPA axis dysregulation, sympathetic overactivation, immune suppression (↓ cytokines, macrophage dysfunction), oxidative stress increase. Clinical: Slower closure in stressed patients (surgical wounds, chronic ulcers, burns); higher complication rates. Stressors: Anxiety, depression, PTSD, socioeconomic factors. Interventions: Mindfulness, CBT, exercise, social support improve outcomes (faster healing, better collagen quality). Calls for routine stress screening in wound clinics and integrated psychosocial care to optimize healing in chronic/complex cases (e.g., DFUs, VLUs).

Key Highlights:

• Mechanisms: Cortisol inhibits collagen/fibroblast function; stress prolongs inflammation.
• Evidence: Delayed healing, reduced tensile strength in stressed models/patients.
• Interventions: Psychological support accelerates recovery.
• Relevance: Holistic approach essential for hard-to-heal wounds; complements advanced therapies.

Read review summary

Keywords: psychological stress, wound healing impairment, collagen production, stress management

Formulation and Application of a Human Insulin-Like Growth Factor-1 Loaded Hydrogel for Diabetic Wound Healing

Summary: This study formulates and evaluates a human insulin-like growth factor-1 (IGF-1)-loaded hydrogel using chitosan/gelatin for diabetic wound healing. IGF-1 promotes cell proliferation, migration, angiogenesis, and ECM remodeling—key in delayed diabetic repair due to hyperglycemia/impaired growth factor signaling. Hydrogel: Biocompatible, pH-responsive, sustained IGF-1 release (over days), maintains bioactivity. In vitro: Enhances fibroblast proliferation/migration, collagen synthesis, VEGF expression. In vivo (STZ-diabetic rat full-thickness wounds): Accelerated closure (significant reduction in wound area by days 7–14), improved granulation, re-epithelialization, collagen deposition/maturation, increased CD31+ vessels vs. blank hydrogel/untreated controls. No cytotoxicity/inflammation; supports moist environment, infection barrier. Positions IGF-1 hydrogel as targeted, controlled-release platform for chronic diabetic ulcers (DFUs), addressing growth factor deficiencies and offering superior outcomes over standard care.

Key Highlights:

• Release: Sustained IGF-1 delivery preserves bioactivity.
• In vitro: ↑ Proliferation/migration, collagen/VEGF.
• In vivo: Faster closure, better angiogenesis/remodeling.
• Relevance: Growth factor-loaded hydrogel as synthetic adjunct for hard-to-heal diabetic wounds.

Read full article

Keywords: IGF-1 hydrogel, diabetic wound healing, growth factor delivery, chitosan gelatin

Revolutionizing Wound Care with Mobile Solutions

Summary: February 2026 feature discusses mobile wound care revolutionizing management of chronic/hard-to-heal wounds (DFUs, VLUs, pressure injuries). Highlights mobile clinics, telehealth integration, portable advanced therapies (dressings, debridement tools, NPWT), and point-of-care diagnostics for rural/underserved patients. Benefits: Reduced travel/hospital visits, timely intervention, better adherence, improved healing rates, cost savings, and QoL gains. Addresses barriers (access, transportation) with patient-centered models; examples include van-based services, app-monitored dressings, and multidisciplinary mobile teams. Emphasizes scalability and future potential in post-pandemic care delivery.

Key Highlights:

• Solutions: Mobile clinics, telehealth, portable tech.
• Impact: Access equity, faster healing, reduced costs.
• Relevance: Complements synthetic/innovative therapies in community settings.

Read article

Keywords: mobile wound care, telehealth wound, rural wound access

Development of a Novel Hydrogel Dressing Loaded with Curcumin and Aloe Vera for Diabetic Wound Healing

Summary: February 2026 study develops a novel hydrogel dressing combining curcumin (anti-inflammatory/antioxidant) and Aloe vera (moisturizing/healing) in chitosan/gelatin base for diabetic wound management. Characterized: Good swelling, sustained release, biocompatibility. In STZ-induced diabetic rats (full-thickness wounds), hydrogel accelerates closure (faster re-epithelialization/collagen deposition), promotes angiogenesis (↑ VEGF/CD31), reduces inflammation (↓ TNF-α/IL-6), and oxidative stress vs. controls. Synergistic effects: Curcumin modulates NF-κB pathway, Aloe vera supports hydration/proliferation. Positions as promising natural/synthetic hybrid for chronic diabetic wounds (DFUs), addressing infection/inflammation barriers with low-cost, bioactive approach. Calls for clinical translation.

Key Highlights:

• Formulation: Curcumin/Aloe vera in chitosan/gelatin hydrogel.
• In vivo: Faster healing, better matrix remodeling.
• Mechanisms: Anti-inflammatory, antioxidant, angiogenic.
• Relevance: Plant-derived adjunct for diabetic chronic wounds.

Read full article (open access)

Keywords: curcumin hydrogel, Aloe vera, diabetic wound healing, bioactive dressing

From Immigrant to Industry Leader: Dr. Robert Abraham Is Reshaping How Clinics Deploy Regenerative Medicine Wound Care

Summary: February 2026 profile highlights Dr. Robert Abraham’s journey from immigrant to regenerative medicine leader in wound care. Emphasizes his work reshaping clinic deployment of advanced therapies (stem cells, growth factors, amniotic/synthetic matrices, biologics) for chronic/hard-to-heal wounds (DFUs, VLUs, pressure injuries). Key innovations: Mobile/outpatient models for accessible care, standardized protocols integrating regenerative products with debridement/offloading/infection control, evidence-based approaches to accelerate healing and reduce amputations/recurrence. Addresses barriers (cost, training, reimbursement) through education, partnerships, and real-world outcomes. Positions him as advocate for equitable access, especially underserved populations; highlights impact on QoL, cost savings, and limb preservation in diabetic/complex cases.

Key Highlights:

• Leadership: Transforms clinic adoption of regenerative tech.
• Focus: Mobile deployment, protocols, outcomes.
• Impact: Faster healing, amputation reduction.
• Relevance: Exemplifies future-oriented regenerative/synthetic integration in practice.

Read profile

Keywords: Dr Robert Abraham, regenerative medicine, mobile wound care, limb preservation

Expectation Versus Reality in Chronic Wound Care

Summary: February 2026 commentary examines the disconnect between expectations and realities in chronic wound management. Ideal: Fast healing, complete closure, minimal scarring, low recurrence with standard care. Reality: Influenced by comorbidities (diabetes, vascular disease, malnutrition), biofilm/infection, patient factors (adherence, mobility), and wound chronicity—leading to prolonged treatment, high recurrence (e.g., 70% in VLUs within 1 year), and amputation risks in DFUs. Discusses clinician/patient frustrations from unmet expectations, over-reliance on “miracle” products, and underestimation of systemic issues. Recommends realistic goal-setting (e.g., percentage area reduction, pain control, infection prevention), multidisciplinary teams (wound specialists, vascular, nutrition, podiatry), evidence-based advanced therapies (synthetics, biologics, NPWT), patient education (lifestyle, adherence), and longitudinal monitoring. Emphasizes QoL improvements over perfect closure; calls for better communication to align expectations and reduce burnout/dissatisfaction.

Key Highlights:

• Gap: Ideal rapid healing vs. real-world slow/recurrent progress.
• Contributors: Comorbidities, biofilm, non-adherence.
• Solutions: Realistic goals, multidisciplinary, education.
• Relevance: Frames expectations for synthetic/innovative therapies in chronic wounds.

Read commentary

Keywords: chronic wound expectations, patient education, multidisciplinary care, recurrence rates

Suprasorb Liquacel Pro / Suprasorb Liquacel Ag

Summary: This product-focused article evaluates the Suprasorb Liquacel family of superabsorbent dressings for managing moderate-to-high exudate in chronic/hard-to-heal wounds (VLUs, DFUs, pressure injuries, surgical sites). Liquacel Pro: non-adherent wound contact layer, superabsorbent polymer core (vertical absorption locks exudate/bacteria/endotoxins), breathable backing prevents maceration, supports autolytic debridement. Liquacel Ag: adds ionic silver for sustained antimicrobial action (effective against bacteria/biofilm in infected/colonized wounds). Benefits: High fluid handling (locks away from peri-wound), reduces dressing changes (up to 7 days), minimizes pain/trauma on removal, promotes moist healing environment, cost-effective (fewer visits). Clinical indications: Exudate management in moderate-high levels, infection control (Ag variant), biofilm disruption support. Practical use: Secondary dressing over primary (e.g., with debridement), suitable for compression. Emphasizes patient comfort, clinician efficiency, and outcomes in real-world chronic wound care.

Key Highlights:

• Absorption: Vertical locking prevents lateral spread/maceration.
• Antimicrobial: Ag variant for sustained release against resistant organisms.
• Benefits: Fewer changes, pain reduction, autolytic support.
• Relevance: Addresses exudate/biofilm challenges in hard-to-heal wounds; complements advanced therapies like synthetics.

Read article

Keywords: Suprasorb Liquacel, superabsorbent dressing, exudate management, ionic silver

Dialkylcarbamoyl Chloride-coated wound dressing: An Evidence Review and Position Document

Summary: Narrative review/position document by international experts advocates DACC-coated dressings for antimicrobial stewardship in wound infection. Mechanism: Hydrophobic binding removes microbes/endotoxins without release, reducing resistance/inflammation vs. silver. Evidence: In vitro rapid binding (S. aureus, P. aeruginosa, biofilms); clinical series/trials show reduced load, improved healing in DFUs/VLUs/burns/SSIs (post-cesarean/vascular), neonatal/pediatric; compatible with NPWT, odor control. Position: Non-antibiotic innovation for prevention/treatment/management in acute/chronic/contaminated wounds; supports AMS amid AMR threats. Recommendations: Use in colonized/infected (polymicrobial/resistant), biofilms; combine with debridement/hydrogels; extended wear. Implications: Reduces complications/costs in hard-to-heal wounds.

Read document

Keywords: DACC-coated, antimicrobial dressing, biofilm management, AMS wound

Use of Negative Pressure Wound Therapy in Selected Cases to Facilitate Abdominal Wound Healing

Summary: November 2025 multiple case series examines NPWT for complex abdominal wounds: dehiscence with exposed bowel (fistula risk), peristomal skin issues (urinary leakage from ileal conduit requiring re-siting), infected incisions/fascial defects. Indications: Surgical dehiscence, peristomal complications. Outcomes: Granulation promotion, wound closure, peristomal skin optimization. Applications: Acute open wounds with exposure/defects; facilitates healing/risk reduction. No specific NPWT types detailed; supports adjunctive use in high-risk abdominal cases.

Read abstract

Keywords: NPWT abdominal, wound dehiscence, peristomal complications

Understanding artificial intelligence: Barriers and potential in wound care

Summary: Consensus document explores AI in wound care. Potential: Diagnosis (image-based classification, dermatologist-level accuracy for DFUs/skin cancer), prediction (healing time/comorbidities/social factors), monitoring (imaging apps/tissue classification), personalized treatment (evidence-based tailoring). Barriers: Data (availability/quality), ethics (privacy, bias/equity), integration (clinician wariness/job impact, EHR challenges). Recommendations: Educate clinicians (AI as tool, not replacement), involve them in implementation/sharing learnings, create equitable/safe systems, address unmet needs (chronic wounds), explore generative AI (documentation/telemedicine). Future: Interdisciplinary research, disrupt efficiency/consistency/scalability. Emphasizes clinician role to tackle global burden.

Key Highlights:

• Potential: Image analysis, prediction, personalized care.
• Barriers: Data/ethics/integration myths.
• Recommendations: Education/involvement, equitable frameworks.
• Relevance: Future tool for diagnosis/monitoring in chronic wounds.

Read consensus document

Keywords: AI wound care, artificial intelligence, consensus document

The prevention and management of skin tears in aged skin

Summary: ‘Made Easy’ guide on skin tears in aged skin (traumatic, non-extending to subcutaneous; ISTAP classification: uncomplicated vs. complicated). Risk factors: Extremes of weight, dementia/agitation, mobility issues, polypharmacy. Prevention: Skincare bundles (pH-balanced cleansers, pat dry, moisturize twice daily with emollient-based products—50% incidence reduction), gentle handling (no aggressive adhesives), education/self-care. Management: Preserve/re-approximate flap (no sutures/adhesives), atraumatic cleansing, silicone dressings (non-adherent, moisture balance, extended wear), UWH (change q5-7 days if no issues). Avoid iodine, strong adhesives, gauze. Use Skin Tone Tool for assessment. Evidence-based: Reduces trauma, promotes healing in frail/elderly; holistic (patient/wound/skin/risk). Implications: Improves QoL, lowers hospitalization/costs amid ageing demographics.

Key Highlights:

• Classification: ISTAP; uncomplicated heal ~4 weeks.
• Prevention: Moisturizers, bundles, handling protocols.
• Management: Silicone/atraumatic, UWH.
• Relevance: Essential for elderly/chronic care.

Read guide

Keywords: skin tears, aged skin, ISTAP classification, prevention bundles

Advancing Knowledge of Acute Cutaneous Graft-Versus-Host Disease Wound Care: A Case Study

Summary: January/February 2026 open-access case study (64-year-old male post-allogeneic HSCT for AML) advances wound care for acute cutaneous GvHD (grade IV stage 4: generalized erythroderma >50% BSA, bullae/desquamation >5%). Wounds on limbs/chest/torso/sacrum at day 38 post-HSCT worsened to severe by day 75 despite systemic (steroids, cyclosporine, methotrexate → tacrolimus/ECP/etanercept/ruxolitinib). Wound care: Gentle hygiene (moisturizing cleanser/warm water), postural changes, nutrition, daily changes with preheated lactated Ringer’s, pain control. Dressings: Soft silicone layer (Mepitel One) for exudative, hydrogel/alginate (Nu-Gel) under silicone for fibrin-covered (q2 days), gauze/tubular net (no adhesives). Outcomes: Reduced exudate/bleeding by day 79, granulation/re-epithelialization by day 83, complete resolution by day 109 (small residuals). No prior standardized recommendations; draws from burn management. Demonstrates atraumatic silicone dressings effective/safe in severe GvHD; calls for large-scale studies.

Key Highlights:

• Dressings: Non-adherent silicone reduced trauma/pain, supported healing.
• Outcomes: Rapid improvement despite complications (TMA).
• Implications: Evidence for topical adjuncts in acute GvHD.
• Relevance: Extends to chronic/immunocompromised wounds.

Read full case study (open access)

Keywords: acute GvHD, soft silicone dressings, HSCT wounds

Advancing Wound Hygiene as a standard protocol for hard-to-heal wounds in APAC and Turkey: Findings from an international meeting

Summary: October 15, 2025 supplement reports findings from August 2025 Beijing meeting (panel: Harikrishna KR Nair et al., >200 years experience). Advocates Wound Hygiene as standard routine protocol at every visit for hard-to-heal wounds: 1) Cleanse wound/surrounding skin, 2) Debride (initial/maintenance), 3) Refashion edges (align skin/bed), 4) Dress with biofilm-targeted therapies. Complements T.I.M.E./T.I.M.E.R.S./Wound Balance/M.O.I.S.T.; prefers “hard-to-heal” over “chronic” to encourage hope/action. Biofilm in 60-100% cases makes protocol biofilm-focused. Consensus: Adopt universally (generalists/specialists), integrate workflows, prioritize education/competencies (tiered training), use digital tools (photography/3D), generate real-world evidence (pilots/registries). Barriers: Patient awareness/delays, provider scope restrictions, system reimbursement/infrastructure gaps. Recommendations: Blended training, local endorsement, phased evidence (minimal datasets), policy engagement for accreditation. Implications: Standardizes care, reduces delays/complications/costs; scalable in diverse APAC/Turkey settings.

Key Highlights:

• Protocol: 4 steps at every change; biofilm-centric.
• Evidence: 94% improvement in European analysis.
• Barriers/Recommendations: Education, tools, real-world data.
• Relevance: Standardizes hygiene for chronic/hard-to-heal wounds.

Read supplement

Keywords: wound hygiene, hard-to-heal wounds, biofilm protocol, APAC consensus

Successful treatment of moderately ischaemic DFUs using intermittent topical oxygen

Summary: December 17, 2025 post hoc analysis from randomized double-blind sham-controlled study evaluates intermittent topical oxygen therapy (TWO2) for moderately ischaemic DFUs (UT grade 1-2, 1-20 cm², 4 weeks-1 year duration, failed ≥4 weeks standard care). Moderate ischemia per IWGDF: ABI ≥0.7, TBI <0.75, monophasic/biphasic Doppler, TcPO₂ <60 mmHg, toe pressure <60 mmHg, or skin perfusion pressure <60 mmHg. TWO2: cyclical pressurized oxygen (up to 10 L/min), non-contact compression (mobilizes fluids, reduces edema, improves inflow), humidification for diffusion. Patient-administered at home. Outcomes: 39% complete healing (100% epithelialization, confirmed over two visits) at 12 weeks vs. 0% sham (p<0.0076, ITT). Mechanisms: Forces oxygen into hypoxic tissue, elevates tension, lowers pH; upregulates NADPH oxidase (antimicrobial), ATP synthase (energy), prolyl/lysyl hydroxylase (collagen cross-linking), NOS (angiogenesis/flow). Reduces inflammation, bioburden; supports granulation/regeneration in ischemic DFUs. Relevant for chronic non-healing despite standard care (debridement, offloading, infection/moisture management); lowers recurrence (6x lower at 12 months in broader studies).

Key Highlights:

• Healing: 39% vs. 0% at 12 weeks; significant in moderate ischemia.
• Multimodal: Oxygen + compression + humidification synergy.
• Implications: Home-based adjunct; targets hypoxia barriers.
• Relevance: Expands options for ischemic/hard-to-heal DFUs.

Read full article

Keywords: TWO2, intermittent topical oxygen, moderately ischaemic DFU, home-based therapy

Sulodexide for limb salvage in refractory diabetic foot ulcer with arteriosclerosis obliterans: a case report

Summary: February 12, 2026 case report describes a 77-year-old female with T2DM, severe DFU, infection, and arteriosclerosis obliterans (ASO). Despite debridement, angioplasty (ABI 0.54 to 0.92), and standard care, wound deteriorated due to persistent microcirculatory dysfunction (TcPO₂ minimal rise from 25.4 to 28.6 mmHg). Sulodexide (glycosaminoglycan: 80% low-molecular-weight heparan sulfate, 20% dermatan sulfate) initiated as salvage (600 LSU/day IV for 51 days) via vasoprotective, anti-thrombotic, hemorheological effects—repairing endothelial glycocalyx, reducing microvascular resistance/pro-thrombotic state. Outcomes: granulation formation, TcPO₂ to 53.6 mmHg, complete epithelialization by April 26, 2025, limb salvaged, no recurrence by July 15, 2025 follow-up. No adverse events; highlights sulodexide as adjunctive/salvage for post-revascularization microcirculatory failure in refractory DFU, hypothesis-generating for trials in endocrinology/diabetology contexts.

Key Highlights:

• Mechanism: Endothelial repair, improved perfusion despite macrovascular success.
• Outcomes: Full healing post-sulodexide; no recurrence/amputation.
• Implications: Targets microvascular issues in ischemic DFUs.
• Relevance: Complements advanced therapies for non-healing post-revascularization cases.

Read full case report

Keywords: sulodexide, refractory DFU, arteriosclerosis obliterans, microcirculatory dysfunction

CAMPs Wound Care Summit 2026

Summary: Third annual Cellular, Acellular, and Matrix-Like Products (CAMPs) Wound Care Summit (live, March 6-7, 2026, Hilton West Palm Beach, FL). Focuses on CAMPs advances, regulatory landscape, clinical innovations, adjuvant therapies. Builds on 2025 (350+ delegates); multidisciplinary audience (researchers, clinicians, industry). Resort venue; call for registration/discounted rooms. Ties to synthetic/matrix breakthroughs for chronic wounds.

Register/Visit site

Keywords: CAMPs Summit, matrix-like products, wound care conference

2026 Wound Care Compliance: Why Your Current Documentation Won’t Survive the Next RAC Audit

Summary: February 12, 2026 Pulse post warns of stricter RAC audits using AI to detect inconsistencies in wound care claims. Vulnerabilities: incomplete measurements/depth/exudate/tissue, missing rationale/guideline ties, continuity gaps, insufficient medical necessity proof. Risks: 15-30% revenue denials, extrapolations, repayments. Fixes: CMS-aligned templates, real-time checks/tech, photographic documentation (scale/timestamps), staff training, quarterly mock audits. Advocates performance-based RCM for proactive compliance and profitability.

Key Highlights:

• Threats: AI-driven scrutiny, vague/templated notes.
• Solutions: Standardized tools, photos, audits.
• Relevance: Essential for sustaining advanced therapies amid policy pressures.

Read full article

Keywords: RAC audit, wound care documentation, compliance 2026

Breaking Up is Hard to Do: Debriding Biofilm Effectively

Summary: This Lohmann-Rauscher educational article addresses the critical role of effective biofilm debridement in managing chronic, hard-to-heal wounds (e.g., DFUs, VLUs, pressure injuries), where biofilm is present in up to 78–100% of cases and contributes to persistent infection, inflammation, and stalled healing. Biofilm forms protective communities of bacteria/fungi embedded in EPS matrix, resisting antimicrobials and immune response. Challenges include hidden/invisible presence, recurrence post-debridement, and incomplete removal leading to reinfection. Strategies discussed: mechanical (sharp, ultrasonic, hydrosurgery), autolytic (moisture balance dressings), enzymatic (collagenase, papain-urea), antimicrobial (silver, iodine, honey, DACC-coated), irrigation (high-pressure, saline). Highlights Debrisoft® monofilament polyester pad as a gentle, effective mechanical option—removes slough, debris, and superficial biofilm without trauma, suitable for painful/sensitive wounds, easy to use in clinic/home. Recommends multimodal approach (combine debridement types + antimicrobial dressings) and regular assessment (e.g., via swabbing/imaging). Stresses early, consistent intervention to break the chronicity cycle, reduce antimicrobial resistance risk, and accelerate healing. Includes practical tips, case examples, and evidence references supporting Debrisoft® in biofilm management.

Key Highlights:

• Biofilm prevalence: 78–100% in chronic wounds; major barrier to healing.
• Debridement types: Mechanical (preferred initial), autolytic/enzymatic (adjunct), antimicrobial (targeted).
• Debrisoft®: Non-traumatic, effective for superficial biofilm/slough; painless, quick, no residue.
• Best practice: Multimodal, regular/repeat sessions; combine with dressings (e.g., DACC, silver).
• Relevance: Supports wound hygiene protocols (cleanse/debride/dress) for hard-to-heal cases; reduces infection risk and supports advanced therapies like synthetics.

Read full article

Keywords: biofilm debridement, Debrisoft, chronic wound biofilm, mechanical debridement, wound hygiene

NurseLearn Conference 2026 | Vision to Impact

Summary: Website for NurseLearn Conference 2026 emphasizes vision-to-impact in nursing education, potentially covering wound care, ostomy, diabetes management, and clinical skills. Specifics on dates, location (virtual/in-person), agenda, speakers, or registration limited due to content access issues. Aligns with ongoing education needs in chronic wound prevention/treatment; may include sessions on advanced therapies, compliance, or patient outcomes. Check site for updates as of Feb 2026.

Visit conference site

Keywords: NurseLearn Conference, nursing education, wound care conference

aFGF rescues high glucose-induced senescent fibroblasts and improves diabetic wound healing by regulating SIRT1/STAT3 pathway

Summary: February 9, 2026 study investigates acidic fibroblast growth factor (aFGF) in diabetic wound healing. In STZ-induced diabetic rats, local aFGF injection accelerates closure and ↓ SASP expression. In vitro (HG-induced L929 fibroblasts), aFGF reverses senescence, boosts antioxidant capacity. Mechanism: rescues SIRT1 expression, inhibits STAT3 phosphorylation in senescent tissue. Positions aFGF as candidate to ameliorate fibroblast dysfunction and promote healing in high-glucose environments.

Key Highlights:

• In vivo: Faster closure, reduced senescence markers.
• In vitro: Anti-senescence/antioxidant effects.
• Pathway: SIRT1/STAT3 modulation key.
• Relevance: Targets cellular aging in diabetic chronic wounds.

Read full article

Keywords: aFGF, senescent fibroblasts, SIRT1/STAT3, diabetic wound

Dermomina® clay achieves high closure rates in non-infected diabetic foot ulcers

Summary: February 11, 2026 pre-experimental observational study (Dominican Republic, March 2022–October 2024) assesses topical Dermomina clay (aluminosilicate) as adjunct in 24 Wagner grade 1-3 DFUs (14 non-infected, 10 infected). Non-infected ulcers showed faster healing (92.9% complete closure by week 20 vs. 40% infected; weekly reduction 12.2% vs. 6.5%; p<0.001). Median closure time shorter in non-infected; factors delaying healing: infection, HbA1c >7%, age >60, size >20 cm², higher Wagner, PAD. Mild/transient AEs (8.3%); no discontinuations/amputations. Supports clay as accessible adjunct for non-infected DFUs; calls for controlled trials to confirm role in evidence-based care.

Key Highlights:

• Outcomes: High closure in non-infected; infection major barrier.
• Safety: Favorable profile; low-cost potential.
• Relevance: Natural adjunct for early-stage DFUs in resource-limited settings.

Read full article

Keywords: Dermomina clay, non-infected DFU, closure rate, adjunctive therapy

Histopathological Evaluation of Bioactive Glass Wound Sites in a Swine Model

Summary: February 11, 2026 open-access study evaluates tissue response to borate-based bioactive glass fiber matrix (BBGFM) in a swine model (Sus scrofa domesticus, n=2 pigs, 12 subcutaneous pockets each). BBGFM applied at 25%, 50%, 100% thickness vs. untreated controls; euthanized at 3/6 weeks for gross/histopathology. Dose-dependent inflammation (macrophage-dominant) at 3 weeks diminished by 6 weeks, indicating resolution and biocompatibility. Enhanced neovascularization (CD31+ vessels), collagen matrix deposition, and maturity across groups (greater fibrosis in higher thickness). Residual BBGFM correlated with initial thickness; promotes controlled inflammation, angiogenesis, ECM remodeling. Positions BBGFM as promising bioactive scaffold for chronic wounds (DFUs, VLUs, pressure injuries), overcoming traditional dressing limitations.

Key Highlights:

• Inflammation: Peaks early, resolves; dose-dependent.
• Regeneration: ↑ angiogenesis, collagen maturity/fibrosis.
• Biocompatibility: No adverse reactions; supports matrix remodeling.
• Relevance: Preclinical evidence for borate-based synthetics in hard-to-heal wounds.

Read full article (open access)

Keywords: bioactive glass, BBGFM, swine wound model, neovascularization

Association between controlling nutritional status (CONUT) score and amputation risk factors in T2DM patients with DFU

Summary: January 28, 2026 retrospective analysis (n=387 T2DM DFU inpatients, Jan 2024–Jun 2025) links CONUT score (albumin, cholesterol, lymphocytes) to amputation. 40.3% amputation rate (all minor); amputation group had worse nutrition (lower albumin/prealbumin/Hb/PNI), higher CONUT, larger ulcers, more osteomyelitis/PAD/smoking. Amputation rose with CONUT severity (15.1% normal → 68.3% moderate-severe). Logistic regression: CONUT (OR=1.655/unit), osteomyelitis (3.817), PAD (12.602) as independent risks. ROC: CONUT AUC=0.705 (cutoff 3.5). Subgroup: association strong except HbA1c <7%. Malnutrition exacerbates healing delays/infection/vascular issues; early CONUT assessment/nutrition improvement could lower amputation in DFU.

Key Highlights:

• Risks: CONUT, osteomyelitis, PAD independent predictors.
• Prediction: Good AUC; higher scores → poorer outcomes.
• Implications: Routine nutritional screening in DFU care.
• Relevance: Systemic factor in chronic diabetic wounds/amputation prevention.

Read full article

Keywords: CONUT score, DFU amputation, nutritional status, T2DM DFU

Silk fibroin wound dressing may reduce wound care complications in TJA

Summary: January 27, 2026 Healio article (Orthopedics Today Hawaii presentation) reports silk fibroin mesh dressing reduces post-TJA wound complications. Retrospective reviews: 257-patient cohort (Justin P. Moo Young et al.) showed no wound issues, 0% allergic contact dermatitis (vs. 6.4% mesh group), lower hypersensitivity. Another comparison confirmed cost savings ($465.91/case average), OR time reduction (3.7 min). Dressing: applied to incision, no glues (avoids hypersensitivity), worn weeks post-op. Expert (Ugo N. Ihekweazu): helpful, patient satisfaction high, no issues. Implications: Safer, efficient alternative for surgical wounds in orthopedics.

Key Highlights:

• Outcomes: 0% complications/dermatitis; cost/time savings.
• Advantages: No glues, extended wear, patient-friendly.
• Relevance: Natural-derived dressing for post-op/surgical wounds.

Read article

Keywords: silk fibroin, TJA wound, post-op dressing, orthopedic wound

BioLab Holdings Announces Investment in Advanced Synthetic Antimicrobial – Tissue Regeneration Solutions

Summary: January 27, 2026 press release: BioLab Holdings (Phoenix) announces strategic investment in Imbed Biosciences (Wisconsin) for SAM™ Antimicrobial Technology and Microlyte® wound matrix. Microlyte®: fully-synthetic, bioresorbable polymer matrix conforms to wound contours, sustains silver antimicrobial (≥72h), maintains moisture, optimizes surface for cell migration/proliferation. Clinical: accelerated reduction/closure in chronic/non-healing wounds. Investment differentiates BioLab’s portfolio (physician office focus), expands distribution, supports next-gen SAM™ platforms (e.g., pain-management integration). Collaboration ensures integration across outpatient/acute/advanced care; addresses biologic variability/supply issues.

Key Highlights:

• Tech: Synthetic, antimicrobial, regenerative matrix.
• Benefits: Consistent, easy-use, infection reduction, healing support.
• Rationale: Portfolio expansion, commercialization acceleration.
• Relevance: Advances synthetic alternatives for chronic wounds.

Read press release

Keywords: Microlyte, SAM technology, synthetic antimicrobial, Biolab Imbed

KCI Introduces New Round and Thin Dressings to Its Vacuum Assisted Closure Products

Summary: KCI introduces round and thin foam dressings optimized for VAC NPWT systems, targeting irregular/small/contoured wounds (e.g., DFUs, surgical, pressure ulcers). Round for focal sites; thin for shallow areas with reduced bulk under drapes. Benefits: superior conformability, seal integrity, patient comfort/mobility, fewer leaks, consistent pressure delivery for granulation/healing. Simplifies use in outpatient/home settings; complements NPWT in complex/chronic cases.

Key Highlights:

• Design: Round (focal), thin (contoured/shallow).
• Advantages: Conformability, seal, reduced changes.
• Applications: Chronic/trauma wounds.
• Relevance: Refines NPWT for hard-to-manage sites.

Read article

Keywords: VAC dressings, NPWT innovations, KCI round thin

Development of a banana stem fiber-reinforced chitosan–xanthan gum wound healing patch loaded with Tridax procumbens extract for biomedical applications

Summary: January 27, 2026 study develops bio-composite wound patch via interpenetrating polymeric network (IPN) of banana pseudo-stem fiber-reinforced chitosan-xanthan gum hydrogel loaded with Tridax procumbens extract (traditional healer). Addresses single-polymer limits (weakness, poor absorption/drug loading) through synergy. Characterized: SEM (rough morphology, uniform fiber dispersion), XRD (78.43% crystallinity), FTIR (bioactive integration). Biologically: 60% antioxidant (IC50 ~7.67 µg/ml), 78% L929 fibroblast scratch closure in 24h at 25 µg/ml extract, 75% viability at 5 µg/ml (MTT). Positions as eco-friendly, bioactive dressing for protection, exudate management, healing promotion in biomedical applications.

Key Highlights:

• Properties: Rough surface, high crystallinity, antioxidant/bioactive.
• In vitro: Strong closure/viability in fibroblasts.
• Implications: Natural/sustainable alternative for chronic wounds.
• Relevance: Aligns with plant-derived/synthetic hybrid innovations.

Read full article

Keywords: banana stem fiber, chitosan xanthan, Tridax procumbens, bio-composite patch

Up to £1.5 million available for innovations that improve conflict wound care

Summary: January 27, 2026 release from UK Defence Innovation (UKDI), on behalf of Dstl and MOD Defence Medical Service, announces up to £1.5 million (excl. VAT) for innovations in conflict wound care under theme “Conflict wounds: from biology to battlefield solutions.” Targets modeling (wound aetiology, novel therapeutics testing) and treatment (reduce morbidity, improve outcomes) for skin/muscle/bone injuries at extremities/torso/maxillofacial. Expects 5-7 awards (£200,000–£300,000 each, flexible). Open to innovators with defence/security relevance, innovative approaches, and applicability to complex conflict wounds. Deadline: midday GMT March 24, 2026. Aims to bridge biology-to-battlefield gaps for practical demonstrations/proofs-of-concept in military/security contexts.

Key Highlights:

• Challenges: Modeling wound biology/therapeutics; treating to lower morbidity.
• Funding: £1.5M total; proposal deadline March 24, 2026.
• Implications: Accelerates innovations for trauma/complex wounds; potential civilian translation.
• Relevance: Supports synthetic/advanced solutions for severe/chronic trauma wounds.

Read news release

Keywords: conflict wound care, UKDI funding, wound innovations, military wound